Online citations, reference lists, and bibliographies.
← Back to Search

Tumour Radiosensitivity Is Associated With Immune Activation In Solid Tumours.

T. Strom, L. Harrison, A. Giuliano, M. Schell, S. Eschrich, Anders E. Berglund, W. Fulp, R. Thapa, D. Coppola, Sungjune Kim, J. Frakes, J. Foekens, J. Mulé, J. Torres-Roca
Published 2017 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE Our goal was to determine whether tumour radiosensitivity is associated with activation of the immune system across all tumour types as measured by two gene expression signatures (GESs). METHODS We identified 10,240 genomically profiled distinct solid primary tumours with gene expression analysis available from an institutional de-identified database. Two separate GESs were included in the analysis, the radiosensitivity index (RSI) GES (a 10-gene GES as a measure of radiosensitivity) and the 12-chemokine (12-CK) signature (a 12-gene GES as a measure of immune activation). We tested whether the RSI and 12-CK were associated with each other across all tumour samples and, in an exploratory analysis, their prognostic significance in predicting distant metastasis-free survival (DMFS) among a well-characterised, independent cohort of 282 early-stage breast cancer cases treated with surgery and post-operative radiation alone without systemic therapy. The lower the RSI score, the higher the tumour radiosensitivity; whereas, the higher the 12-CK score the higher the immune activation. RESULTS Using an RSI cut-point of ≤0.3745, RSI-low tumours (n = 4,291, 41.9%) had a significantly higher median 12-CK GES value (0.54 [-0.136, 1.095]) compared with RSI-high tumours (-0.17 [-0.82, 0.42]; p < 0.001) across all tumour samples, indicating that radiosensitivity is associated with immune activation. In an exploratory analysis of early-stage breast cancer cases, a multivariable model with patient age, RSI and 12-CK provided a strong composite model for DMFS (p = 0.02), with RSI (hazard ratio [HR] 0.63 [95% confidence interval 0.36, 1.09]) and 12-CK (HR 0.66 [0.41, 1.04]) each providing comparable contributions. CONCLUSIONS Tumour radiosensitivity is associated with immune activation as measured by the two GESs.
This paper references
10.1016/S1470-2045(15)70076-8
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
J. Weber (2015)
10.1093/BIOSTATISTICS/4.2.249
Exploration, normalization, and summaries of high density oligonucleotide array probe level data.
R. Irizarry (2003)
10.1158/0008-5472.CAN-04-1525
Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes
C. T. Garnett (2004)
10.1002/ijc.22851
Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysis
C. Ragin (2007)
10.1016/S1470-2045(15)00083-2
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
A. Ribas (2015)
10.1016/j.radonc.2015.07.018
Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.
T. Strom (2015)
10.1056/NEJMoa1414428
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A. Postow (2015)
10.1056/NEJMoa1510665
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
R. Motzer (2015)
10.1016/j.ctrv.2015.03.011
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.
K. Reynders (2015)
10.1056/NEJMoa1412082
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
10.1016/j.ijrobp.2015.01.036
Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection.
K. Ahmed (2015)
10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
10.1016/j.semradonc.2014.07.003
Current clinical trials testing combinations of immunotherapy and radiation.
M. Crittenden (2015)
10.1016/j.ctrv.2015.11.001
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Xiangjiao Meng (2015)
10.18632/oncotarget.5437
The radiosensitivity index predicts for overall survival in glioblastoma
K. Ahmed (2015)
10.1016/J.IJROBP.2003.09.012
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.
S. Demaria (2004)
10.1038/srep00765
12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
J. Messina (2012)
10.1186/bcr1325
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts
Y. Pawitan (2005)
10.1056/NEJMoa1504030
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
10.1089/cbr.2013.1578
Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions.
M. B. Bernstein (2014)
10.1016/j.ijrobp.2015.06.021
Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.
J. Torres-Roca (2015)
10.1097/PPO.0b013e318238216e
Implementing personalized medicine in a cancer center.
D. Fenstermacher (2011)
10.1158/2326-6066.CIR-15-0143
Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response
M. Mihm (2015)
10.1016/j.ijrobp.2012.03.017
The abscopal effect associated with a systemic anti-melanoma immune response.
Emily F. Stamell (2013)
10.1056/NEJMoa1112824
Immunologic correlates of the abscopal effect in a patient with melanoma.
M. Postow (2012)
10.1186/1748-717X-9-98
Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells
F. Wirsdörfer (2014)
10.1093/bioinformatics/19.2.185
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias
B. Bolstad (2003)
10.1158/2326-6066.CIR-14-0196
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
A. Sharabi (2014)
10.1016/j.oraloncology.2014.11.001
Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response.
C. Tang (2015)
10.1016/j.ijrobp.2009.05.056
Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform.
S. Eschrich (2009)
10.1016/j.semradonc.2014.07.001
Seminars in Radiation Oncology. Introduction.
S. Formenti (2015)
10.1158/0008-5472.CAN-05-0656
Prediction of radiation sensitivity using a gene expression classifier.
J. Torres-Roca (2005)
10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
10.1038/nrc3958
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
H. Barker (2015)
10.1016/S1470-2045(15)70122-1
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
A. Eggermont (2015)
10.1016/j.ajpath.2011.03.007
Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling.
D. Coppola (2011)
10.1016/j.ijrobp.2009.06.014
A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation.
S. Eschrich (2009)
10.1158/1078-0432.CCR-12-0891
Validation of a Radiosensitivity Molecular Signature in Breast Cancer
S. Eschrich (2012)
10.1186/1471-2105-14-153
Iterative rank-order normalization of gene expression microarray data
E. A. Welsh (2012)
10.1084/jem.20052494
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
E. Reits (2006)
10.4049/jimmunol.1200563
Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
A. Gupta (2012)
10.1002/1097-0142(197702)39:2+<737::AID-CNCR2820390708>3.0.CO;2-M
The effects of therapeutic irradiation on lymphocytes and immunity
S. Order (1977)
10.1056/NEJMoa0912217
Human papillomavirus and survival of patients with oropharyngeal cancer.
K. Ang (2010)
Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium.
D. Hallahan (1996)
10.1056/NEJMoa1503093
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
Prognostic and predictive markers for the new immunotherapies.
K. Mahoney (2014)
10.1056/NEJMoa1411087
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
S. Ansell (2015)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.1016/S0140-6736(05)17947-1
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Y. Wang (2005)
10.1038/nrd4591
Combination cancer immunotherapy and new immunomodulatory targets
K. Mahoney (2015)
10.1038/nature14292
Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer
Christina Twyman-Saint Victor (2015)
10.1158/0008-5472.CAN-14-1258
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
S. Dovedi (2014)
10.1158/1078-0432.CCR-09-0265
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody
M. Z. Dewan (2009)
10.1016/j.ijrobp.2010.09.034
Radiation enhances regulatory T cell representation.
Evelyn L. Kachikwu (2011)
10.1093/NAR/GNG015
Summaries of Affymetrix GeneChip probe level data.
R. Irizarry (2003)
10.1016/S1470-2045(15)00007-8
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
A. Sharabi (2015)



This paper is referenced by
10.1038/s41573-018-0004-1
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen (2018)
10.3390/ijms20153635
Radiosensitivity Differences between EGFR Mutant and Wild-Type Lung Cancer Cells are Larger at Lower Doses
Mai Anakura (2019)
10.2217/fon-2017-0468
Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC.
X. S. Sun (2018)
10.1177/1073274818815504
The Future of Radiation Oncology in Soft Tissue Sarcoma
A. Naghavi (2018)
10.18632/oncotarget.27631
Exploring the role of survivin in neuroendocrine neoplasms
A. Hanif (2020)
10.1016/J.TRECAN.2019.06.006
Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy.
H. Enderling (2019)
10.20944/preprints202001.0155.v1
Cancer-associated Fibroblasts: Origins, Heterogeneity and Functions in Tumor Microenvironment
K. Dzobo (2020)
10.3389/fimmu.2019.00333
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
A. Vilgelm (2019)
10.1101/2020.02.11.944512
Harnessing tumor immune ecosystem dynamics to personalize radiotherapy
G. Daniel Grass (2020)
10.1109/ACCESS.2019.2952916
Hadron Therapy Based on Laser Acceleration in the Plasma Channel Using Oxygen Ionization
Vala Mehryar Alviri (2019)
10.1155/2018/6729802
Personalizing Radiation Treatment Delivery in the Management of Breast Cancer
K. Ahmed (2018)
10.1186/s13058-018-0978-y
Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
M. Sjöström (2018)
10.1016/j.ebiom.2019.08.019
Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management
K. Ahmed (2019)
10.1667/RADE-20-00013
Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy
A. Lee (2020)
10.1038/s41419-019-1769-9
Clinical update on head and neck cancer: molecular biology and ongoing challenges
E. Alsahafi (2019)
10.2217/epi-2019-0108
Genomic stratification based on radiosensitivity and PD-L1 for tailoring therapeutic strategies in cervical cancer.
Xintong Lyu (2019)
10.1016/J.CANRAD.2019.07.152
Outils pour la prédiction de la réponse tumorale et des tissus sains en oncologie radiothérapie
O. Riou (2019)
10.1038/s41568-019-0144-6
Tertiary lymphoid structures in the era of cancer immunotherapy
C. Sautès-Fridman (2019)
10.3390/ijms20020382
Cytokine Modulation in Breast Cancer Patients Undergoing Radiotherapy: A Revision of the Most Recent Studies
Raffaella Marconi (2019)
Semantic Scholar Logo Some data provided by SemanticScholar